Peritoneal Cancer Clinical Trials in New York, New York
9 recruitingNew York, New York
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled164 locationsNCT06824467
Recruiting
Phase 3
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled59 locationsNCT05659381
Recruiting
Phase 1Phase 2
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting
Phase 1
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Solid TumorFallopian Tube CancerEpithelial Ovarian Cancer+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc172 enrolled24 locationsNCT04516447
Recruiting
Phase 2
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Ovarian CancerOvarian CarcinomaFallopian Tube Cancer+7 more
Memorial Sloan Kettering Cancer Center86 enrolled7 locationsNCT06290193
Recruiting
Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Stage IV Ovarian Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Advanced Ovarian Carcinoma+22 more
M.D. Anderson Cancer Center580 enrolled19 locationsNCT04575935
Recruiting
Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AbbVie520 enrolled264 locationsNCT05445778
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer+2 more
Regeneron Pharmaceuticals890 enrolled51 locationsNCT03564340
Recruiting
Phase 1Phase 2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ovarian CancerEndometrial CancerPrimary Peritoneal Cancer+1 more
Regeneron Pharmaceuticals612 enrolled24 locationsNCT04590326